We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+45.08%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$930M
AUM Growth
+$84.2M
Cap. Flow
-$119M
Cap. Flow %
-12.76%
Top 10 Hldgs %
65.22%
Holding
58
New
12
Increased
4
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
RGLS
Regulus Therapeutics
RGLS
+$70.3M
2
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$22M
3
CHRS icon
Coherus Oncology
CHRS
+$21.9M
4
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$20M
5
TGTX icon
TG Therapeutics
TGTX
+$16.7M

Top Sells

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$64.2M
2
DYAX
DYAX CORPORATION
DYAX
+$35.8M
3
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$34.8M
4
DVAX
Dynavax Technologies
DVAX
+$17.4M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 64.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMO
1
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$91.6M 9.85%
6,000,000
– –
BCRX icon
2
BioCryst Pharmaceuticals
BCRX
$2.42B
$85.7M 9.21%
7,050,356
-18,803
-0.3% -$208K
ACHN
3
DELISTED
Achillion Pharmaceuticals
ACHN
$82.1M 8.82%
6,700,000
– –
RGLS
4
DELISTED
Regulus Therapeutics
RGLS
$76.1M 8.18%
+39,524
New +$70.3M
DYAX
5
DELISTED
DYAX CORPORATION
DYAX
$69.5M 7.47%
4,945,697
-2,863,442
-37% -$35.8M
TGTX icon
6
TG Therapeutics
TGTX
$8.15B
$53.1M 5.7%
3,350,449
+1,284,878
+62% +$16.7M
BLUE
7
DELISTED
bluebird bio
BLUE
$46.4M 4.99%
39,073
-17,191
-31% -$11.5M
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$40M 4.3%
2,428,571
– –
ACAD icon
9
CALL
Acadia Pharmaceuticals
ACAD
$4.48B
$31.8M 3.41%
1,000,000
-4,250,000
-81% -$121M
ACHN
10
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$30.6M 3.29%
2,500,000
-500,000
-17% -$6.11M
CHRS icon
11
Coherus Oncology
CHRS
$217M
$25.4M 2.73%
+1,555,355
New +$21.9M
ZSPH
12
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$23.5M 2.52%
564,483
– –
LRMR icon
13
Larimar Therapeutics
LRMR
$379M
$22.6M 2.43%
61,080
– –
XNCR icon
14
Xencor
XNCR
$1.43B
$22.4M 2.41%
1,399,423
+150,500
+12% +$1.75M
FWP
15
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$20.2M 2.17%
+138,657
New +$20M
NVAX icon
16
Novavax
NVAX
$1.21B
$19.2M 2.07%
162,054
-91,300
-36% -$9.54M
SGMO
17
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$18.6M 1.99%
1,220,209
– –
TRVN
18
DELISTED
Trevena, Inc.
TRVN
$17.8M 1.91%
+4,759
New +$15.8M
JUNO
19
DELISTED
Juno Therapeutics, Inc.
JUNO
$14.6M 1.57%
+280,000
New +$12.5M
TXMD icon
20
TherapeuticsMD
TXMD
$23.4M
$14.3M 1.54%
64,223
-4,864
-7% -$1M
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$13.9M 1.5%
310,554
-278,387
-47% -$11.7M
TARA icon
22
Protara Therapeutics
TARA
$213M
$13M 1.4%
+31,250
New +$12.6M
TENX icon
23
Tenax Therapeutics
TENX
$393M
$10.3M 1.1%
83
+10
+14% +$1.21M
BLCM
24
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$9.34M 1%
+102,640
New +$22M
AUPH icon
25
Aurinia Pharmaceuticals
AUPH
$1.94B
$9.01M 0.97%
+2,474,076
New +$8.81M
1
2 3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, RA Capital Management held 58 positions worth $930M, up 10% from $846M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

RA Capital Management withdrew a net $119M in Q4 2014, closing 7 positions and reducing 10 holdings. Its most notable exit was AVANIR PHARMACEUTICALS, INC CL A, an estimated $64.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 50% a quarter earlier.

Against the trend, RA Capital Management opened a new position in Regulus Therapeutics worth $76.1M.

  • RA Capital Management's largest Q4 2014 buy was Regulus Therapeutics: 39,524 shares worth $76.1M.
  • RA Capital Management added most to TG Therapeutics in Q4 2014, an estimated $16.7M increase.
  • RA Capital Management's biggest Q4 2014 reduction was DYAX CORPORATION, cutting an estimated $35.8M.
  • RA Capital Management fully exited AVANIR PHARMACEUTICALS, INC CL A in Q4 2014, selling an estimated $64.2M.
  • RA Capital Management's ten largest holdings make up 65% of its $930M portfolio in Q4 2014.
  • RA Capital Management opened 12 new positions and closed 7 in Q4 2014.
  • RA Capital Management's portfolio value rose 10% quarter-over-quarter to $930M.

Based on RA Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.